Lenalidomid +pharma (Lenalidomide)

Lenalidomide is used in hematologic malignancies and related syndromes, targeting abnormal cell growth and immune dysregulation.

• Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
• Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.
• Mantle cell lymphoma: contributes to disease control when combined with other agents in relapsed settings.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering ubiquitination of transcription factors such as Ikaros and Aiolos. This leads to reduced cytokine production, inhibition of angiogenesis, and induction of apoptosis in malignant plasma cells and other hematologic tumor cells, while modulating the immune microenvironment.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require hydration.
• Rash: mild skin eruptions or itching.
• Nausea: occasional upset stomach.
• Low blood counts: reduced neutrophils, platelets, or red cells.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Secondary malignancies: emergence of new cancers.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe infections: opportunistic or bacterial infections requiring prompt treatment.

Before initiating therapy, clinicians should assess patient risk factors and monitor laboratory parameters regularly.

• Pregnancy risk: contraindicated in pregnancy; use effective contraception.
• Thrombosis risk: evaluate need for prophylactic anticoagulation.
• Renal function: adjust monitoring for patients with impaired kidney function.
• Hepatic function: monitor liver enzymes in patients with liver disease.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct light.

Lenalidomide can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma concentrations.
• Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine): may enhance immunomodulatory effects.
• CYP3A4 inhibitors (e.g., ketoconazole): may modestly increase exposure.
• Vaccines: live attenuated vaccines should be avoided during treatment.
• NSAIDs: may increase risk of thrombosis when combined with lenalidomide.